Instruction for use: Cordanum

Active substance: Talinolol

ATX Code C07AB13 Talinolol

Pharmacotherapeutic group:

Beta-blockers

The nosological classification (ICD-10)

I10 Essential (primary) hypertension

Hypertension, Arterial hypertension, Arterial hypertension crisis course, Essential Hypertension

Primary hypertension, Arterial hypertension, complications of diabetes, hypertension, The sudden increase in blood pressure, Hypertensive disorders of blood circulation, hypertensive condition, hypertensive crises, hypertension, arterial Hypertension, malignant Hypertension, Hypertonic disease, Hypertensive crisis, Hypertension, accelerated hypertension, malignant hypertension, The aggravation of hypertensive disease, Transient hypertension, Isolated systolic hypertension

I15 Secondary hypertension

Arterial hypertension, complications of diabetes, hypertension, The sudden rise in blood pressure, Hypertensive disorders of blood circulation, hypertensive condition, hypertensive crises, hypertension, arterial hypertension, malignant hypertension, Hypertensive crisis, Hypertension, accelerated hypertension, malignant hypertension, hypertensive crisis, The aggravation of hypertensive disease, Transient hypertension, hypertension, Arterial hypertension, Arterial hypertension crisis course, renovascular hypertension, symptomatic hypertension, renal hypertension, Renovascular hypertension, Symptomatic hypertension

I20 Angina [angina]

Heberden disease; Angina pectoris; The attack of angina pectoris; recurrent angina; Spontaneous angina; Stable angina pectoris; Angina rest; Angina progressing; Angina mixed; Angina spontaneous; stable angina; Chronic stable angina; Angina Syndrome X

I21 Acute myocardial infarction

Myocardial infarction in the acute phase, Acute Myocardial Infarction, Myocardial infarction with pathologic Q wave and without, Myocardial infarction complicated by cardiogenic shock, Infarction left ventricular, Transmural myocardial infarction, Myocardial infarction netransmuralny (subendocardial), Netransmuralny myocardial infarction, Subendocardial myocardial infarction, The acute phase of myocardial infarction, Acute myocardial infarction, Sub-acute phase of myocardial infarction, Subacute phase of myocardial infarction, Thrombosis of the coronary arteries (the arteries), Threatened myocardial infarction, Myocardial infarction without Q wave

I25 Chronic ischemic heart disease

Coronary heart disease on the background of hypercholesterolemia; Coronary heart disease is a chronic; Coronary heart disease; Stable coronary artery disease; Percutaneous transluminal angioplasty; Myocardial ischemia, arteriosclerosis; Recurrent myocardial ischemia

I25.2 Transferred last myocardial infarction

Cardiac syndrome, Myocardial infarction, post-MI, Rehabilitation after myocardial infarction, Reocclusion of the operated vessel, Angina postinfarctnaya, Status after myocardial infarction, myocardial infarction

I47.1 Supraventricular tachycardia

Supraventricular paroxysmal tachycardia; supraventricular tachyarrhythmia; supraventricular tachycardia; Supraventricular arrhythmias; Supraventricular paroxysmal tachycardia; supraventricular tachyarrhythmias; supraventricular tachycardia; Neurogenic sinus tachycardia; orthodromic tachycardia; Paroxysmal supraventricular tachycardia; Paroxysm of supraventricular tachycardia; Paroxysm of supraventricular tachycardia with WPW-syndrome; Paroxysm of atrial tachycardia; Paroxysmal supraventricular tachyarrhythmia; Paroxysmal supraventricular tachycardia; Politopnye atrial tachycardia; Atrial fibrillation; Atrial tachycardia is true; Atrial tachycardia; Atrial tachycardia with AV block; reperfusion arrhythmias; Reflex Bertsolda-Jarisch; Recurrent sustained supraventricular paroxysmal tachycardia; Symptomatic ventricular tachycardia; Sinus tachycardia; Supraventricular paroxysmal tachycardia; supraventricular tachyarrhythmia; supraventricular tachycardia; supraventricular arrhythmia; supraventricular arrhythmias; Tachycardia of AV connections; supraventricular tachycardia; Tachycardia orthodromic; sinus tachycardia; The nodal tachycardia; Chaotic atrial tachycardia politopnye; Wolff-Parkinson-White

I47.2 Ventricular tachycardia

Torsades de pointes (torsade de pointes), Symptomatic ventricular tachycardia, Torsades de pointes in myocardial infarction, Ventricular fibrillation, Ventricular tachycardia , Ventricular tachyarrhythmias, Life-threatening ventricular arrhythmias, Sustained ventricular tachycardia, Sustained monomorphic ventricular tachycardia, Paroxysmal ventricular tachycardia torsades, Paroxysmal ventricular tachycardia

Composition

Film-coated tablets 1 tablet.

talinolol 50 mg

card of 10 pieces; 5 blisters per box.

Pharmacological Properties
Pharmachologic effect

antianginal, antihypertensive, anti-arrhythmic.

Selectively blocking beta1-adrenergic receptors.

pharmacodynamics

Decreases automaticity of sinus node, it slows heart rate slows AV conduction, reduces the excitability of myocardial contractility and cardiac output and myocardial oxygen demand.

Clinical pharmacology

Eliminates the stimulating effect of catecholamines on the heart with physical and psycho-emotional stress. The hypotensive effect is stabilized by the end of 2 weeks course of treatment. It reduces the frequency and severity of angina attacks; aids in limiting infarct and reduces the risk of arrhythmia on a background of myocardial infarction, thereby reducing the mortality and frequency of relapses. The average therapeutic doses has a less pronounced (compared to non-selective beta-blockers) influence on bronchial smooth muscle, myometrium, and peripheral arteries.

Indications

Hypertension, angina pectoris (prevention of attacks), paroxysmal rhythm disturbances (mild and prevention), cardiopsychoneurosis of hypertensive type, acute myocardial infarction (with strict contra account); secondary prevention of myocardial infarction.

Contraindications

Hypersensitivity, circulatory insufficiency II-IV NYHA stages on, sick sinus syndrome, sinuauricular and AV block II and III degree, sinus bradycardia (heart rate less than 50 beats / min.), Severe hypotension, cardiogenic shock; acute myocardial infarction complicated by bradycardia, hypotension, left ventricular failure; asthma, pheochromocytoma (without the use of alpha-blockers).

Pregnancy and breast-feeding

Perhaps if the expected effect of therapy outweighs the potential risk to the fetus.

Side effects

From the nervous system and sensory organs: rarely - dizziness, headache, sleep disturbances, blurred vision, sedation, in rare cases - anxiety, depression, hallucinations, psychosis, convulsions.

Cardio-vascular system and blood (blood, hemostasis): possible sinus bradycardia, AV block I degree, excessive lowering of blood pressure, rarely - cold extremities.

From the digestive tract: dyspepsia, abdominal cramping, cholestatic hepatotoxicity - single cases.

From the respiratory system: rarely - bronchospasm.

For the skin: rarely - psoriasis, alopecia.

Other: reduction of potency, increase in body weight, rarely - sweating, reduced secretion of tear fluid.

Interaction

Enhance the hypotensive effect of diuretics, vasodilators, calcium channel blockers (nifedipine) and other antihypertensives.; verapamil, diltiazem, and general anesthetics potentiate the effects cardiodepressive, reserpine, clonidine and methyldopa - bradycardia. Compounding the negative chrono and Dromotropic cardiac glycosides and negative inotropic impact of antiarrhythmic agents of class 1A (quinidine, disopyramide, amiodarone, propanamide), the effect of muscle relaxants antidepolyarizuyuschih. You can change the effects of insulin and oral hypoglycemic agents (required level of blood sugar control). Do not assign both MAO inhibitors (except type B), because possible sharp rise in blood pressure. NSAIDs may reduce the hypotensive effect.

Dosing and Administration

Inside for 0.5-1 hour before meals, with liquid squeezed small amount of liquid. Dose set individually depending on the severity of disease and the sensitivity to the drug.

Treatment started with a low dose - 50 mg (Table 1). 1-2 times daily or 100 mg (2 tablets). 1 time per day.

Usually, no special medical requirements are guided by the following approximate application circuits:

- Hypertension - 100 mg / day (. Table 2) in the morning, with little effect dose can be increased to 300 mg / day;

- Chronic stable angina - in mild cases, 50 mg (1 tab.) In the morning and evening (100 mg / day), the average dose - 50-100 mg 1-2 times a day, in severe cases, the dose can be increased to 300 mg / day;

- Cardiac arrhythmia - an initial dose of 150 mg / day (. Table 3), and then, if necessary, gradually increase the dose to 300 mg / day;

- Cardiopsychoneurosis of hypertensive type - depending on the overall condition of the patient is often sufficient dose of 50 mg 1-2 times a day, in rare cases, it can be increased to 300 mg / day;

- Heart attack - after the initial on / in the talinolol on the 2nd or 3rd day of treatment, switch to oral administration at a dose of 50-100 mg 2 times a day (100-200 mg / day), the maximum - 300 mg / day;

- Secondary prevention of myocardial infarction - in the late period postinfarction drug administered in the same doses as in the stable angina, an average of 50-100 mg (1-2 tablets.), 2 times a day (100-200 mg / day).

The interval between administration of a single dose should be 12-24 hours. The duration of reception depends on the clinical picture of the disease and tolerability.

Precautionary measures

Caution must be exercised in obstructive respiratory diseases, expressed violations of peripheral blood circulation, diabetes, metabolic acidosis, psoriasis. Do not assign patients Prinzmetal angina, drivers of vehicles and people skills relate to the high concentration of attention. Stop receiving should gradually, within 1-2 weeks, in order to avoid the syndrome of "cancellation".

Storage conditions

In a dry, dark place at a temperature no higher than 30 ° C.

Keep out of the reach of children.

shelf life

3 years.

Do not use beyond the expiration date printed on the package.